Tagrisso (osimertinib) — Medica
Non-Small Cell Lung Cancer – Advanced or Metastatic Disease
Initial criteria
- age ≥ 18 years
- Patient has epidermal growth factor receptor (EGFR) mutation-positive disease as detected by an approved test OR (Patient has EGFR T790M mutation-positive disease as detected by an approved test AND has progressed on treatment with at least one EGFR tyrosine kinase inhibitor [erlotinib, Iressa, Vizimpro, Gilotrif])
Approval duration
1 year